Satish Garg, MD Appointed New Editor-in-Chief of Leading Diabetes Technology Journal.

NEW ROCHELLE, N.Y. -- Satish K. Garg, MD, Professor of Medicine and Pediatrics and Director, Adult Program, Barbara Davis Center for Childhood Diabetes, University of Colorado at Denver and Health Sciences Center, has been appointed the new Editor-in-Chief of Diabetes Technology & Therapeutics, a MEDLINE journal published by Mary Ann Liebert, Inc., publishers, effective immediately. Jay S. Skyler, MD, MACP, Professor of Medicine, Pediatrics, and Psychology, in the Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Miami, Miami, Florida, will be joining the Journal as Associate Editor. Other key diabetologists including John Buse, MD, PhD, Lois Jovanovic, MD, Howard Wolpert, MD, and H. Peter Chase, MD have joined the new editorial team which along with our current Editorial Board, will ensure the editorial integrity of the Journal and provide quality information that fosters the application of new technology and therapeutics to patient care. A free sample issue of the journal can be viewed online at www.liebertpub.com/dia

Satish K. Garg, MD has research interests that include the early detection and treatment of renal and retinal complications of type 1 diabetes and the development of new diagnostic and therapeutic tools related to clinical diabetes management that include new insulin analogs and glucose sensors. Dr. Garg is board certified in internal medicine, endocrinology, and diabetes, and is a member of many organizations including the International Diabetes Federation, the American Diabetes Association, the Endocrine Society of India, the European Association for the Study of Diabetes, the Regional Pediatric Endocrine Society of Colorado, the Research Society for the Study of Diabetes Mellitus, and numerous other professional societies in both the United States and India. He is an international lecturer and speaker, and has published many chapters in books, is on the editorial boards for many international diabetes journals, and has published more than 147 original papers in peer-review journals.

Jay S. Skyler, MD, MACP, is currently a Professor of Medicine, Pediatrics, and Psychology, in the Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Miami. He is Chairman of the NIH (NIDDK)-sponsored Type 1 Diabetes TrialNet, a nationwide network conducting clinical trials to prevent type 1 diabetes or interdict the type 1 diabetes disease process. He is a past President of the American Diabetes Association, the International Diabetes Immunotherapy Group, and the Southern Society for Clinical Investigation, and was a Vice-President of the International Diabetes Federation. He served as a member of the Endocrinology, Diabetes, and Metabolism Subspecialty Examining Board of the American Board of Internal Medicine, as Chairman of the Council of Subspecialty Societies of the American College of Physicians (ACP) and a member of the ACP Board of Regents. Dr. Skyler was founding Editor-in-Chief of Diabetes Care, and currently is Scientific Editor of International Diabetes Monitor.

Diabetes Technology & Therapeutics is a peer-reviewed journal published bimonthly that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Technologies of interest include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of contents and a free sample issue may be viewed online at www.liebertpub.com/dia

Mary Ann Liebert, Inc., is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Metabolic Syndrome & Related Disorders, Obesity Management, Human Gene Therapy, and Disease Management. Its biotechnology trade magazine, Genetic Engineering News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 60 journals, newsmagazines, and books is available at www.liebertpub.com.